ORGANIZATION INFO.
CENTOGENE is a global precision medicine company advancing the diagnosis and treatment of rare and neurodegenerative diseases by integrating clinical, genetic, and biochemical data into actionable insights for patients, physicians, and biopharma partners. Founded in 2006 and headquartered in Rostock, Germany, the company operates worldwide and has built one of the largest bio-databank for rare diseases, supporting rapid, reliable diagnostics and data‑driven research collaborations. Its offerings span whole genome and whole exome sequencing, targeted NGS panels, and multiomic analytics, complemented by platforms that streamline expert variant interpretation and clinical decision‑making. With more than one million individuals represented and 350+ peer‑reviewed publications, CENTOGENE provides real‑world evidence that accelerates drug discovery, development, and clinical trials for targeted therapies.
CENTOGENE APAC brings this mission to the Asia–Pacific region, connecting diverse populations to advanced genetic testing and precision medicine programs with local presence and multilingual clinical support. By leveraging the scale and diversity of CENTOGENE’s biodata assets and end‑to‑end diagnostic portfolio, CENTOGENE APAC enables earlier and more accurate diagnoses, supports equitable access to high‑quality testing, and strengthens partnerships with regional health systems and biopharma. The APAC organization focuses on tailoring solutions and workflows to the regional needs, improving patient identification for rare and neurodegenerative conditions, and delivering timely insights that inform prevention, diagnosis, and treatment across rapidly evolving healthcare markets.
